Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.249 EUR | +0.20% | -0.99% | +8.26% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 13.94 | 10.27 | 7.587 | 24.37 | 17.44 | 1.653 |
Enterprise Value (EV) 1 | 15.92 | 6.062 | 6.331 | 14.17 | 10.42 | 1.105 |
P/E ratio | -2.5 x | -0.38 x | -7.28 x | -1.75 x | -1.07 x | -0.09 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 59.6 x | - | 49.3 x | 696 x | 528 x | - |
EV / Revenue | 68 x | - | 41.1 x | 405 x | 316 x | - |
EV / EBITDA | -3.37 x | -1.32 x | -1.57 x | -2.44 x | -0.78 x | -0.09 x |
EV / FCF | -4.66 x | 2.59 x | -1.06 x | -3.46 x | -1.42 x | -0.15 x |
FCF Yield | -21.4% | 38.7% | -94.7% | -28.9% | -70.6% | -665% |
Price to Book | -3.63 x | -3.95 x | -4.12 x | 3.43 x | 3.86 x | -1.65 x |
Nbr of stocks (in thousands) | 21.9 | 101 | 130 | 434 | 745 | 1,360 |
Reference price 2 | 635.0 | 102.0 | 58.20 | 56.20 | 23.40 | 1.216 |
Announcement Date | 30/04/18 | 12/04/19 | 22/04/20 | 28/04/21 | 22/04/22 | 24/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Net sales | - | 0.154 | 0.035 | 0.033 | - |
EBITDA 1 | -4.593 | -4.044 | -5.807 | -13.44 | -11.99 |
EBIT 1 | -4.616 | -4.064 | -5.824 | -13.46 | -12.01 |
Operating Margin | - | -2,638.96% | -16,640% | -40,790.91% | - |
Earnings before Tax (EBT) 1 | -10.74 | -0.86 | -10.41 | -14.45 | -15.13 |
Net income 1 | -10.73 | -0.861 | -10.4 | -14.45 | -15.13 |
Net margin | - | -559.09% | -29,728.57% | -43,793.94% | - |
EPS 2 | -269.8 | -8.000 | -32.16 | -21.90 | -12.86 |
Free Cash Flow 1 | 2.345 | -5.997 | -4.091 | -7.361 | -7.349 |
FCF margin | - | -3,894.07% | -11,688.21% | -22,305.3% | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 12/04/19 | 22/04/20 | 28/04/21 | 22/04/22 | 24/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | 4.2 | 1.26 | 10.2 | 7.02 | 0.55 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | 2.34 | -6 | -4.09 | -7.36 | -7.35 |
ROE (net income / shareholders' equity) | 329% | 38.6% | -356% | -237% | -937% |
ROA (Net income/ Total Assets) | -106% | -81.3% | -58.8% | -82.4% | -100% |
Assets 1 | 10.13 | 1.059 | 17.7 | 17.54 | 15.12 |
Book Value Per Share 2 | -25.80 | -14.10 | 16.40 | 6.060 | -0.7400 |
Cash Flow per Share 2 | 42.70 | 10.60 | 21.90 | 12.70 | 2.690 |
Capex 1 | 0.01 | 0.02 | 0.04 | 0.01 | 0.02 |
Capex / Sales | - | 10.39% | 111.43% | 42.42% | - |
Announcement Date | 12/04/19 | 22/04/20 | 28/04/21 | 22/04/22 | 24/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+8.26% | 7.56M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ALTME Stock
- Financials TME Pharma N.V.